Monitoring illicit psychostimulants and related health issues

Brunt, T.M.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
References


(BZP-party pills) amongst young people in New Zealand. *Harm Reduct. J.* 4, 18


Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA. (2002). The content of ecstasy tablets: implications for the study of their long-term effects. *Addiction* 97, 1531-1536


on snorting, smoking, swallowing and injecting. *Addiction* 103(7), 1174-1186


Docherty JR, Green AR. (2010). The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine
(MDMA, ecstasy) and its derivatives. *Br. J. Pharmacol.* 160(5), 1029-1044


Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM,


Henderson, LA, Glass, WJ. (1994). LSD: Still with Us after All These Years. Wiley & Sons, John Incorporated, San Fransisco, CA


Jaehne EJ, Salem A, Irvine RJ. Pharmacological and behavioral derterminants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia. *Psychopharmacology (Berl)* 194(1), 41-52


determining pill content and purity: Implications for policy and practice. Int. J. Drug Policy 17, 464-472


Legleye S, Ben Lakhdar C, Spilka S.(2008). Two ways of estimating the euro value of the illicit market for cannabis in France. Drug Alcohol Rev. 27(5), 466-472


McCann UD, Ridenour A, Shaham Y, Ricaurte GA. (1994). Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10(2), 129-138


191


McCann UD, Eligulashvili V, Ricaurte GA. (2000). (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42(1), 11-16


Parrott AC. (2004a). MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. *Neuropsychobiology* 50(4), 329-335


Parrott AC. (2006). MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. *J. Psychopharmacology* 20, 147-163


Tancer M, Johanson CE. (2003). Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Dependence 72, 33-44

Tanner-Smith EE. (2006). Pharmacological content of tablets sold as "ecstasy": results from an online testing service. Drug Alcohol Dependence 83, 247-254


Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. (2007). A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). Neuroscience 146(2), 509-514


United States Drug Enforcement Administration. (2010). *Cocaine.* http://www.justice.gov/ndic/pubs31/31379/cocaine.htm#Figure3

http://www.justice.gov/dea/programs/forensicsci/microgram/bulletins_index.html


